Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | GLI1 | P08151 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.82 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.82 |
| ▸ | CES2 | O00748 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betulinic Acid SCHEMBL14436762 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL3525115 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL13814590 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL10015159 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL13637571 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL23132693 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL9110960 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL22251646 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL21264235 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL3896475 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196890-A1 | TGR5 AGONIST COMPLEXES FOR TREATING DIABETES AND CANCER | CITY OF HOPE | 2017-07-13 | — | — | US | disclosed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2252154-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | disclosed |
| EP-2252155-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT INHIBITING THE GROWTH OF MICRO-ORGANISMS AND FOR MAXIMIZING THE EFFECT | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | disclosed |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | BIONICHE ANIMAL HEALTH USA, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | BIONICHE ANIMAL HEALTH USA, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9012666-B2 | Method for producing 30-halogenated betulinic acid | WENZHOU UNIVERSITY (CN) | 2015-04-21 | — | — | US | disclosed |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| EP-2088152-A1 | N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | Institut Neftekhimii I Kataliza Rossiiskoi Akademii Nauk (RU) | 2009-08-12 | — | — | EP | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
| US-7414042-B2 | Method and composition for selectively inhibiting melanoma | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414042-B2 | Method and composition for selectively inhibiting melanoma | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007141389-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141392-A2 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141391-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| US-20070160691-A1 | Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECH (KR) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | RORC 62/4885PTPN1 4535/4885GPBAR1 380/4885 |
| US-20070160691-A1 | Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract | CASP3, BAX, NFATC1 | RORC 947/4885PTPN1 2247/4885GPBAR1 3855/4885 |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | RORC 41/4885PTPN1 3699/4885GPBAR1 1220/4885 |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | NR3C1, NR5A1, NR3C2 | RORC 953/4885PTPN1 855/4885GPBAR1 230/4885 |
| US-20170196890-A1 | TGR5 AGONIST COMPLEXES FOR TREATING DIABETES AND CANCER | GLP1R, GCGR, GPR119 | RORC 2046/4885PTPN1 1960/4885GPBAR1 6/4885 |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | RORC 41/4885PTPN1 3699/4885GPBAR1 1220/4885 |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | RORC 514/4885PTPN1 3468/4885GPBAR1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.